IP Library Granted Patent US 9,603,744
Granted Patent B2
US 9,603,744 · App. 13/796,047 · Granted Mar 28, 2017

Adaptable patient interface

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,603,744
App. No.
13/796,047
Granted
Mar 28, 2017
Kind
B2
Abstract

Systems and methods are described for stabilizing an eye for an ocular laser procedure while minimizing corneal distortions which can adversely affect a surgical laser beam. For the systems, a patient interface includes a contact element for stabilizing the eye and establishing a conformal interface with the anterior surface of the cornea. More specifically, devices are disclosed which overlay both a central corneal region and a peripheral corneal region. In some embodiments, a first material is used in the contact element to overlay the central corneal region and a second material is used in the contact element to overlay the peripheral corneal region. Typically, the first and second materials differ in terms of hardness and deformability. In another embodiment disclosed herein, a contact element having a viscoelastic material for stabilizing an eye for a laser procedure is described.

Claims (19)

1. A patient interface for stabilizing an eye of a patient during an ophthalmic laser procedure which comprises:

a substantially circular, disk-shaped central portion defining an axis and a periphery, wherein the periphery is in a plane perpendicular to the axis and is located at a radial distance “r 1 ” from the axis, and further wherein the central portion is formed with a contact surface having a nominal radius of curvature “R 1 ” when the central portion is in contact with the eye, and is made of a transparent material having a hardness “h 1 ”; and

an annular-shaped peripheral portion having an inner radius equal to “r 1 ” and an outer radius of “r 2 ”, wherein the peripheral portion extends from the periphery of the central portion to establish the peripheral portion as an extension of the central portion beyond the distance “r 1 ” from the axis, wherein the peripheral portion is formed with a contact surface having a nominal radius of curvature “R 2 ” when the peripheral portion is in contact with the eye, and wherein the peripheral portion is made of a transparent material having a hardness “h 2 ”, wherein “h 1 ≠ h 2 ” and “R 1 <R 2 ”.

2. A patient interface as recited in claim 1 wherein the peripheral portion is a solid material.

3. A patient interface as recited in claim 1 wherein “h 1 >h 2 ”.

4. A patient interface as recited in claim 1 wherein “h 1 <h 2 ”.

5. A patient interface as recited in claim 1 wherein said central portion has a curvature between 35-45 diopters.

6. A patient interface as recited in claim 1 wherein said peripheral portion is a liquid crystal material.

7. A patient interface as recited in claim 1 wherein said central and peripheral portions are contiguous.

8. A patient interface as recited in claim 1 wherein said central portion substantially stabilizes the eye to reduce the effects of heartbeat induced ocular movements to a level suitable for a selected laser procedure.

9. A patient interface as recited in claim 1 further comprising an imaging system for real-time adjustment of alignment and docking pressure between said patient interface and said eye.

10. A patient interface for stabilizing an eye of a patient during an ophthalmic laser procedure which comprises:

a substantially circular, disk-shaped central portion defining an axis and a periphery, wherein the periphery is in a plane perpendicular to the axis and is located at a radial distance “r 1 ” from the axis, and further wherein the central portion is formed with a contact surface having a radius of curvature “R 1 ” when the central portion is in contact with the eye, and is made of a transparent material; and

an annular-shaped peripheral portion having an inner radius less than “r 1 ”, wherein the peripheral portion is an extension of the central portion, is a liquid, and is held between the central portion and the eye by capillary forces, and wherein the peripheral portion is established having a radius of curvature “R 2 ”, with “R 1 <R 2 ”.

11. A patient interface as recited in claim 10 wherein the peripheral portion has an outer radius substantially equal to “r 1 ”.

12. A patient interface as recited in claim 10 wherein said peripheral portion is a liquid gel.

13. A patient interface as recited in claim 10 wherein said central portion has a curvature between 35-45 diopters.

14. A patient interface as recited in claim 10 wherein said central portion substantially stabilizes the eye to reduce the effects of heartbeat induced ocular movements to a level suitable for a selected laser procedure.

15. A patient interface as recited in claim 10 further comprising an imaging system for real-time adjustment of alignment and docking pressure between said patient interface and said eye.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2013
From: HAILMANN, MARKUS; DAMBACHER, FLORIAN; LOESEL, FRIEDER; MOSEDALE, GWILLEM
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 030259/0696 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2013
From: HAILMANN, MARKUS; DAMBACHER, FLORIAN; LOESEL, FRIEDER; MOSEDALE, GWILLEM
To: TECHNOLAS PERFECT VISION GMBH
Reel/Frame 030259/0898 →